167 related articles for article (PubMed ID: 36893945)
1. The biology and treatment of leiomyosarcomas.
Kerrison WGJ; Thway K; Jones RL; Huang PH
Crit Rev Oncol Hematol; 2023 Apr; 184():103955. PubMed ID: 36893945
[TBL] [Abstract][Full Text] [Related]
2. Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome.
Cui RR; Wright JD; Hou JY
BJOG; 2017 Jun; 124(7):1028-1037. PubMed ID: 28128524
[TBL] [Abstract][Full Text] [Related]
3. Management of advanced uterine leiomyosarcoma.
Hyman DM; Grisham RN; Hensley ML
Curr Opin Oncol; 2014 Jul; 26(4):422-7. PubMed ID: 24840518
[TBL] [Abstract][Full Text] [Related]
4. Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
Ricci S; Stone RL; Fader AN
Gynecol Oncol; 2017 Apr; 145(1):208-216. PubMed ID: 28209496
[TBL] [Abstract][Full Text] [Related]
5. Soft Tissue and Uterine Leiomyosarcoma.
George S; Serrano C; Hensley ML; Ray-Coquard I
J Clin Oncol; 2018 Jan; 36(2):144-150. PubMed ID: 29220301
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
[TBL] [Abstract][Full Text] [Related]
7. Uterine leiomyosarcoma: present management.
Giuntoli RL; Bristow RE
Curr Opin Oncol; 2004 Jul; 16(4):324-7. PubMed ID: 15187886
[TBL] [Abstract][Full Text] [Related]
8. Novel Therapeutics in the Treatment of Uterine Sarcoma.
Bose S; Schwartz GK; Ingham M
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():900-909. PubMed ID: 35714303
[TBL] [Abstract][Full Text] [Related]
9. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas.
Veras E; Zivanovic O; Jacks L; Chiappetta D; Hensley M; Soslow R
Am J Surg Pathol; 2011 Nov; 35(11):1626-37. PubMed ID: 21921786
[TBL] [Abstract][Full Text] [Related]
10. Management of sarcomas of the uterus.
Novetsky AP; Powell MA
Curr Opin Oncol; 2013 Sep; 25(5):546-52. PubMed ID: 23942299
[TBL] [Abstract][Full Text] [Related]
11. Optimal management of uterine leiomyosarcoma.
O'Cearbhaill R; Hensley ML
Expert Rev Anticancer Ther; 2010 Feb; 10(2):153-69. PubMed ID: 20131992
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours].
Croce S; Devouassoux-Shisheboran M; Pautier P; Ray-Coquard I; Treilleux I; Neuville A; Arnould L; Just PA; Le Frere Belda MA; Averous G; Leroux A; Bataillon G; Mery E; Loussouarn D; Weinbreck N; Le Guellec S; Mishellany F; Morice P; Guyon F; Genestie C
Bull Cancer; 2024 Jan; 111(1):97-116. PubMed ID: 37806863
[TBL] [Abstract][Full Text] [Related]
13. Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas.
Tantari M; Barra F; Di Domenico S; Ferraioli D; Vellone VG; De Cian F; Ferrero S
Expert Opin Pharmacother; 2019 Apr; 20(6):713-723. PubMed ID: 30724615
[TBL] [Abstract][Full Text] [Related]
14. Literature review of outcomes and prevalence and case report of leiomyosarcomas and non-typical uterine smooth muscle leiomyoma tumors treated with uterine artery embolization.
Kainsbak J; Hansen ES; Dueholm M
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():130-7. PubMed ID: 26117442
[TBL] [Abstract][Full Text] [Related]
15. Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma.
Giuntoli RL; Lessard-Anderson CR; Gerardi MA; Kushnir CL; Cliby WA; Metzinger DS; Gostout BS
Int J Gynecol Cancer; 2013 Jun; 23(5):869-76. PubMed ID: 23669444
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological treatment for uterine leiomyosarcomas.
Gadducci A; Guerrieri ME
Expert Opin Pharmacother; 2015 Feb; 16(3):335-46. PubMed ID: 25418060
[TBL] [Abstract][Full Text] [Related]
17. Copper ions are novel therapeutic agents for uterine leiomyosarcoma.
Kakuda M; Matsuzaki S; Ueda Y; Shiomi M; Matsuzaki S; Kimura T; Fujita M; Egawa-Takata T; Kobayashi E; Serada S; Yoshino K; Naka T; Kimura T
Am J Obstet Gynecol; 2020 Jan; 222(1):64.e1-64.e16. PubMed ID: 31351063
[TBL] [Abstract][Full Text] [Related]
18. Clinical management of uterine sarcomas.
Amant F; Coosemans A; Debiec-Rychter M; Timmerman D; Vergote I
Lancet Oncol; 2009 Dec; 10(12):1188-98. PubMed ID: 19959075
[TBL] [Abstract][Full Text] [Related]
19. Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy.
Ray-Coquard I; Rizzo E; Blay JY; Casali P; Judson I; Hansen AK; Lindner LH; Dei Tos AP; Gelderblom H; Marreaud S; Litière S; Rutkowski P; Hohenberger P; Gronchi A; van der Graaf WT
Gynecol Oncol; 2016 Jul; 142(1):95-101. PubMed ID: 27208537
[TBL] [Abstract][Full Text] [Related]
20. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
